The relationship between dietary quality, serum brain-derived neurotrophic factor (BDNF) level, and the Val66met polymorphism in predicting depression

Froud, Amy; Murphy, Julie; Cribb, Lachlan; Ng, Chee H.; Sarris, Jerome

doi:10.1080/1028415x.2017.1415281

Cited by 18 publications

(11 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, another study indicated that when Met allele carriers were exposed to a high-CHO diet, their chance of developing carbohydrate-induced hypertriglyceridemia enhanced 49 . In contrast, another study has shown, Val66Met polymorphism did not appear to affect the link between food quality and BDNF serum in terms of depression prediction 50 . Previous research has revealed that dietary intakes alter the relationship between BDNF genotype and obesity-related behaviors, which is corroborated by findings in rats 51 – 53 .…”

Section: Discussionmentioning

confidence: 74%

Interaction between dietary total antioxidant capacity and BDNF Val66Met polymorphism on lipid profiles and atherogenic indices among diabetic patients

Abaj

Rafiee

Koohdani

2021

Sci Rep

View full text Add to dashboard Cite

Brain-derived neurotrophic factor (BDNF) belongs to the “neurotrophin” family of growth factors, and it has recently been associated to cardiovascular disease (CVD). We anticipated that BDNF Val66Met polymorphisms may alter CVD risk markers such as serum lipid profile differences, and interaction with total antioxidant capacity of diet (DTAC) could alter these clinical parameters. This cross-sectional study consisted of 667 diabetic patients (39.7% male and 60.3% female). DTAC was calculated by international databases. Biochemical markers including total cholesterol (TC), low-density lipoprotein (LDL), high-density lipoprotein (HDL), triglyceride (TG), superoxide dismutase (SOD), C-reactive protein (CRP), total antioxidant capacity (TAC), pentraxin-3 (PTX3), isoprostaneF2α (PGF2α). interleukin 18 (IL18), leptin and ghrelin were measured by standard protocol. Atherogenic indices (AIP, AC, CR-I, CR-II) were calculated. Genotyping of the BDNF Val66Met polymorphisms was conducted by the real-time PCR–RFLP method. The gene-diet interactions were evaluated using a generalized linear mode (GLMs). Carriers of the Val/Met genotype who were in the higher median intake of FRAP had lower HDL (P:0.04) and higher TG (P:0.005), AIP (P:0.02) and AC (P:0.02) index compared to Val/Val genotypes with lower median intake. Moreover, diabetic patients with Val/Met genotype who consumed higher ORAC intake had increased odds for anthropometric indices (BMI (P:0.01) and WC (P:0.03)), lipid profiles (TG) (P:0.01), and atherogenic index (AIP) (P:0.02), also decreased odds for HDL (P:0.03) concentration compared to reference group whit lower ORAC intake. Individuals with Val/Met genotype who consumed higher TRAP intake had increased odds for WC (P:0.04), TC (P:0.001), TG (P < 0.001), AIP (P < 0.001) and AC (P < 0.001). Finally, Val/Met patients with a higher median intake of TEAC had higher TG (P:0.02), AIP (P:0.009) and AC (P:0.03) compared to the reference group whit lower TEAC intake. Our study showed that Val/Met genotype had also the highest lipid profile and atherogenic indices even in the highest adherence to DTAC. While it seems that the presence of the Val/Val wild-type and BDNF Met/Met homozygotes in diabetic patients with a high DTAC is a protective factor.

show abstract

Section: Discussionmentioning

confidence: 74%

Interaction between dietary total antioxidant capacity and BDNF Val66Met polymorphism on lipid profiles and atherogenic indices among diabetic patients

Abaj

Rafiee

Koohdani

2021

Sci Rep

View full text Add to dashboard Cite

show abstract

“…The BDNF Val66Met (rs6265) genetic variant has been evaluated in several populations, such as Americans [16], Brazilians [26], Argentineans [25], and Malaysians [20]. In these studies, the polymorphic A (Met) allele seems to be somehow related to MDD, either by reducing [16] or raising [21,26] BDNF protein levels or even by increasing the risk [16,20,25] or protection against [23] disease development. Namely, no conformity is present in the literature regarding the rs6265 polymorphism presence and the MDD occurrence.…”

Section: Bdnf Gg (Val/val) Genotype Frequency In Differentmentioning

confidence: 99%

“…When observing only the BDNF Val66Met (rs6265) genetic variant frequency and genotypic distribution (Table 1), the GG (Val/Val) genotype was frequent in more than 50% of the MDD sample studied in 65% of the analyzed studies [17,18,19,21,23,25,26,[30][31][32][33] (Figure 3). Its frequency is lower in only few studies [16,20,22,[27][28][29].…”

Section: Bdnf Gg (Val/val) Genotype Frequency In Differentmentioning

confidence: 99%

“…Antidepressant use might affect the BDNF protein serum levels [19,20]. Froud et al [21] found that the recent use of antidepressants in the last 12 months was a substantial factor for changes in the BDNF protein serum levels. Chiou and Huang [58] noted the BDNF plasma protein levels were lower in MDD patients taking antidepressants for the first time than the group considered healthy, which might have led to the assumption of BDNF having a fundamental role in the serotonergic system that causes neurobiological and clinical changes.…”

Section: Bdnf Genetic Variant and Treatment Responsementioning

confidence: 99%

See 1 more Smart Citation

BDNF Genetic Variant and Its Genotypic Fluctuation in Major Depressive Disorder

Siqueira

Gontijo

Santos

et al. 2021

Behavioural Neurology

View full text Add to dashboard Cite

Major depressive disorder (MDD) still has an unknown etiology and mechanisms. Many studies have been conducted seeking to associate and understand the connection of different genetic variants to this disease. Researchers have extensively studied the brain-derived neurotrophic factor (BDNF) Val66Met genetic variant in MDD; yet, their findings remain inconsistent. This systematic review sought to verify the GG (Val/Val) genotype frequency fluctuation in different populations with MDD. For this, we searched in different databases and, after applying the eligibility criteria, selected 17 articles. Most studies demonstrate the higher frequency of the ancestral (wild) GG (Val/Val) genotype, although associations of the polymorphic A (Met) allele, changes in BDNF protein serum levels, or both were also found in MDD, whether related to the disease’s development or other factors. Nevertheless, despite these findings, disagreements between several studies are seen. For this reason, further BDNF Val66Met genetic variant studies should not only bridge the gap in the knowledge of this polymorphism’s role in MDD’s different facets but also analyze the genotypic and phenotypic heterogeneity in different populations to help provide a better quality of life for patients.

show abstract

“…Genetic influence on the development of MDD is indicated by the heritability of between 40 to 75% [16][17][18][19][20][21]. Single nucleotide polymorphisms of a number of genes such as tryptophan hydroxylase-1 (TPH1), tryptophan hydroxylase-2 (TPH2) gene and brainderived neurotrophic factor (BDNF) gene have been associated with MDD [22][23][24][25][26]. A point mutation in the SLC30A3 gene, particularly rs11126936 SNP, has been shown to be associated with schizophrenia in genomewide association studies [27] and low blood zinc levels [28].…”

Section: Introductionmentioning

confidence: 99%

Zinc transporter-3 [SLC30A3 (rs11126936)] polymorphism is associated with major depressive disorder in Asian subjects

et al. 2019

View full text Add to dashboard Cite

Major depressive disorder (MDD) compromises the individual’s capacity for self-care and productivity. Single nucleotide polymorphisms (SNP) of a number of genes have been associated with MDD. The zinc transporter-3 protein, encoded by the ZnT3 (SLC30A3) gene, maintains zinc-glutamate homeostasis at the glutamatergic synapse, a disruption of which increases risk of MDD. We hypothesise that variation in SLC30A3 (rs11126936) SNP increases risk of MDD. We recruited 300 MDD cases and 300 controls, matched in the ratio of 1:1 by age, gender and ethnicity. PCR-restriction fragment length polymorphism analysis was used in DNA genotyping, validated by sequencing 10% of samples. Deviation from the Hardy-Weinberg equilibrium was tested using the chi-square test. Conditional logistic regression was used to estimate adjusted odds ratios, controlling for age, gender, ethnicity, occupation and family monthly income. Genotypes G/G and G/T showed two times greater odds of developing MDD compared to variant genotype T/T (OR=1.983, 95% CI=1.031-3.815; p=0.040 and OR=2.232, 95% CI=1.100-4.533; p=0.026 respectively). Carriers of genotypes G/G and G/T of the SNP rs11126936 in SLC30A3 are associated with increased risk of MDD.

show abstract

The relationship between dietary quality, serum brain-derived neurotrophic factor (BDNF) level, and the Val66met polymorphism in predicting depression

Cited by 18 publications

References 33 publications

Interaction between dietary total antioxidant capacity and BDNF Val66Met polymorphism on lipid profiles and atherogenic indices among diabetic patients

Interaction between dietary total antioxidant capacity and BDNF Val66Met polymorphism on lipid profiles and atherogenic indices among diabetic patients

BDNF Genetic Variant and Its Genotypic Fluctuation in Major Depressive Disorder

Zinc transporter-3 [SLC30A3 (rs11126936)] polymorphism is associated with major depressive disorder in Asian subjects

Contact Info

Product

Resources

About